HeartSciences Inc. (HSCS)
NASDAQ: HSCS · Real-Time Price · USD
3.720
-0.010 (-0.27%)
Oct 8, 2025, 4:00 PM EDT - Market closed
HeartSciences Revenue
HeartSciences had revenue of $1.90K in the quarter ending July 31, 2025. This brings the company's revenue in the last twelve months to $6.25K, down -66.40% year-over-year. In the fiscal year ending April 30, 2025, HeartSciences had annual revenue of $4.35K, down -76.61%.
Revenue (ttm)
$6.25K
Revenue Growth
-66.40%
P/S Ratio
1,575.92
Revenue / Employee
$417
Employees
15
Market Cap
9.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.35K | -14.25K | -76.61% |
| Apr 30, 2024 | 18.60K | 13.45K | 261.17% |
| Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
| Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
| Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HSCS News
- 27 days ago - HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results - GlobeNewsWire
- 7 weeks ago - HeartSciences Announces Conference Participation and Investor Webinar - GlobeNewsWire
- 2 months ago - HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results - GlobeNewsWire
- 4 months ago - HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis - GlobeNewsWire
- 4 months ago - Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value - GlobeNewsWire
- 4 months ago - HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone - GlobeNewsWire
- 5 months ago - HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025 - GlobeNewsWire
- 5 months ago - HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson - GlobeNewsWire